Clinical Trial Update: Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease [Phase 1]

View source ↗

Summary

Phase 1 trial assessing Lexiscan (regadenoson), an adenosine A2A receptor agonist, in children and adults with sickle cell disease; the study has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Lexiscan (regadenoson)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Sickle Cell Disease | Phase 1 | Status: COMPLETED | Results posted: 2014-03-07